Praxis Begins Patient Recruitment for Pediatric Epilepsy Research Program
Brentwood, TN
Praxis a company specializing in centralized patient recruitment and retention for clinical research studies, will provide patient recruitment services to a top pharmaceutical company for a study on pediatric epilepsy. This study explores a drug’s effectiveness in very young children. Praxis’ experiences with hard to reach and specialized patient populations is extensive and includes a number of pediatric trials.
Praxis’ successful experiences with hard to reach and specialized patient populations is extensive, and includes a number of pediatric trials. Praxis has helped sponsors successfully enroll pediatric studies:
on average 2 months ahead of schedule
with retention rates most often at 96%, and
with sponsors achieving ROI from ~$1M to ~$3M
“Any time we create and manage a trial involving children there is a real added focus on understanding the mother’s perspective and concerns. We seek to really connect with the mother through images and words that speak to the heart. And by providing content that educates and informs the mom about options, the indication, and the medical research study at hand.” Donna Beasley, VP of operations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
